Matulonis, U. A., Monk, B. J., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N. G., … Moore, K. N. (2019). Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer. In Gynecologic Oncology (Vol. 154, pp. 3–3). Elsevier BV. https://doi.org/10.1016/j.ygyno.2019.04.017

Matulonis, U. A., B. J. Monk, A. A. Secord, M. A. Geller, D. S. Miller, N. G. Cloven, G. F. Fleming, et al. “Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer.” In Gynecologic Oncology, 154:3–3. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.017.

Matulonis UA, Monk BJ, Secord AA, Geller MA, Miller DS, Cloven NG, et al. Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer. In: Gynecologic Oncology. Elsevier BV; 2019. p. 3–3.

Matulonis, U. A., et al. “Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer.” Gynecologic Oncology, vol. 154, Elsevier BV, 2019, pp. 3–3. Crossref, doi:10.1016/j.ygyno.2019.04.017.

Matulonis UA, Monk BJ, Secord AA, Geller MA, Miller DS, Cloven NG, Fleming GF, Hendrickson AEW, Azodi M, DiSilvestro PA, Oza AM, Cristea M, Berek JS, Chan JK, Li Y, Luptakova K, Hazard SJ, Moore KN. Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer. Gynecologic Oncology. Elsevier BV; 2019. p. 3–3.